Details for New Drug Application (NDA): 213978
The generic ingredient in TYRVAYA is varenicline tartrate. There is one drug master file entry for this compound. Thirty suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.
Summary for 213978
| Tradename: | TYRVAYA |
| Applicant: | Oyster Point Pharma |
| Ingredient: | varenicline tartrate |
| Patents: | 12 |
Pharmacology for NDA: 213978
| Mechanism of Action | Cholinergic Agonists Partial Cholinergic Nicotinic Agonists |
Medical Subject Heading (MeSH) Categories for 213978
Suppliers and Packaging for NDA: 213978
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978 | NDA | Harrow Eye, LLC | 73521-030 | 73521-030-02 | 2 BOTTLE, PUMP in 1 CARTON (73521-030-02) / 4.2 mL in 1 BOTTLE, PUMP |
| TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978 | NDA | Harrow Eye, LLC | 73521-030 | 73521-030-90 | 1 BOTTLE, PUMP in 1 CARTON (73521-030-90) / 4.2 mL in 1 BOTTLE, PUMP |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SPRAY;NASAL | Strength | EQ 0.03MG BASE/SPRAY | ||||
| Approval Date: | Oct 15, 2021 | TE: | RLD: | Yes | |||||
| Patent: | 10,456,396 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
| Patent: | 11,224,598 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
| Patent: | 11,903,941 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
Complete Access Available with Subscription
